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Abstract: Chemotherapy-induced nausea and vomiting (CINV) is
presented in over 30% of cancer patients receiving highly/moderately
emetogenic chemotherapy (HEC/MEC). The currently recommended
antiemetic therapy is merely based on the emetogenic level of che-
motherapy, regardless of patient’s individual risk factors. It is, therefore,
critical to develop an approach for personalized management of CINV
in the era of precision medicine.
A number of variables were involved in the development of CINV.
In the present study, we pooled the data from 2 multi-institutional
investigations of CINV due to HEC/MEC treatment in Asian countries.
Demographic and clinical variables of 881 patients were prospectively
collected as defined previously, and 862 of them had full documentation
of variables of interest. The data of 548 patients from Chinese institu-
tions were used to identify variables associated with CINV using
multivariate logistic regression model, and then construct a personalized
prediction model of nomogram; while the remaining 314 patients out of
China (Singapore, South Korea, and Taiwan) entered the external
validation set. C-index was used to measure the discrimination abilityong Xue, MD, PhD MD, PhD,
exandre Chan, PharmD, MPH, and Li Zhang, MD
body surface area, emetogenicity of chemotherapy, and antiemetic
regimens. The C-index was 0.67 (95% CI, 0.62–0.72) for the training
set and 0.65 (95% CI, 0.58–0.72) for the validation set. The C-index was
higher than that of any single predictor, including the emetogenic level
of chemotherapy according to current antiemetic guidelines. Calibration
curves showed good agreement between prediction and actual occur-
rence of CINV.
This easy-to-use prediction model was based on chemotherapeutic
regimens as well as patient’s individual risk factors. The prediction
accuracy of CINV occurrence in this nomogram was well validated by
an independent data set. It could facilitate the assessment of individual
risk, and thus improve the personalized management of CINV.
(Medicine 95(2):e2476)
Abbreviations: 5HT3-RA = 5-hydroxytryptamine3 receptor
antagonists, BSA = body surface area, CI = confidence interval,
CINV = chemotherapy-induced nausea and vomiting, ESMO =
European Society for Medical Oncology, HEC = highly emetogenic
chemotherapy, MASCC = Multinational Association for Supportive
Care in Cancer, MEC = moderately emetogenic chemotherapy,
NCCN = National Comprehensive Cancer Network, NK1-RA =
Neurokinin-1 receptor antagonists, PrACTICE = Pan Australasian
Chemo-Therapy InduCed Emesis burden study, PS = performance
status, QOL = quality of life, VP = vomiting pregnancy.
INTRODUCTION
C hemotherapy-induced nausea and vomiting (CINV) is anobvious and distressing adverse event associated with cancer
treatment, which compromised both therapeutic effects and
patient quality of life (QOL).1–3 Despite the development of
modern antiemetic therapy,4 including the serotonin antagonists
(5HT3-RA) and neurokinin-1 receptor antagonists (NK1-RA),
more than 30% of cancer patients still experience CINV
after receiving highly/moderately emetogenic chemotherapy
(HEC/MEC).5–8 CINV is stubborn to treat after its initial out-
break, as it is poorly responsive to salvage therapy and increases
the probability of subsequent CINV onsets.9,10 However, the
current recommendations in antiemetic guidelines are merely
based on the emetogenic levels of chemotherapy,11,12 regardless
of patient’s individual conditions. Therefore, it is critical to
develop an approach of personalized management of CINV based
on the individual risk prediction, which could guide more effec-
tive antiemetic prophylaxis prior to chemotherapy.licated condition, whose development
f variables.1 Female, young age, low
higher emetogenicity of chemotherapy,
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presence of anxiety and fatigue, and even patient’s expectation
of CINV have been implicated to increase the risk of CINV.13,14
To date, several mathematical prediction models have been
developed to calculate patients’ risks of CINV, which stratified
patents into high- or low-risk groups based on their risk
scores.15–18 However, the complex arithmetic resulted in poor
feasibility, and thus limited their application in clinical practice.
Furthermore, it remains not enough to stratify patients by risk
grouping in the era of precision medicine; healthcare pro-
fessionals need more accurate approach to individually assess
each patient’s risk of CINV development in daily practice.
Nomogram has been employed to quantify the probability
of a clinical event by combining multiple variables
associated.19,20 Its user-friendly graphical interfaces promote
the popularity of nomogram in clinician’s decision-making. The
present study aimed to develop and externally validate a prag-
matic nomogram that individually predicts the occurrence of
CINV in patients receiving HEC/MEC. The patient data were
obtained from a large-scale randomized, multicenter, phase III
trial of CINV prevention in China (Aprepitant P169 study)21
and an observational study of CINV burden in multiple Asian
Pacific countries (PrACTICE study).7
METHODS
Patient Selection
The recruited patients of this analysis were from 2 inde-
pendent studies of CINV prevention in Asian countries. In the
P169 study,21 a total of 412 patients from 16 investigational
centers were evaluable for CINV in the first cycle of chemother-
apy, thus enrolled into this analysis. All the patients were
chemo-naive and randomly assigned to receive NK1-RA
(n¼ 209) or placebo (n¼ 212) combined with 5HT3-RA and
corticosteroid for prevention of CINV due to HEC. While in the
PrACTICE study, 7 a total of 684 patients in 6 countries were
documented of CINV prevention after a single-day HEC or
MEC treatment in daily practice. Considering the therapeutic
disparities among different countries as described previously,22
we only recruited the 486 patients from China (n¼ 153),
Singapore (n¼ 57), South Korea (n¼ 151), and Taiwan
(n¼ 125) in this study. All of the patients enrolled were from
East-Asian population.
To construct a nomogram including both HEC and MEC
populations, we pooled all subjects from China as the training
set, including patients in P169 study (HEC population) and
those in PrACTICE study (HEC and MEC populations). The
data of the remaining patients out of China were used for
external validation of the nomogram. Both the studies had been
approved by institutional review boards of each participating
institution, so the present analysis got a waiver of additional
ethical approval.
Factor Collection
To explore the predictors of CINV occurrence, we
examined the following demographic and clinical variables
of interest: sex, age, body surface area (BSA), alcohol con-
sumption, history of vomiting pregnancy (VP), history of
motion sickness, emetogenicity of chemotherapy, performance
status (PS), and antiemetic regimens.
Based on sex and history of VP, the population was cate-
Hu et algorized asmale, femalewithout VP, and femalewith VP. Alcohol
consumption was classified as less than or 1 time per week on
average in consuming alcoholic drinks. The emetogenicity of
2 | www.md-journal.comchemotherapy was classified as highly/moderately emetogenic
chemotherapy (HEC/MEC) according to MASCC/ESMO 2010
Guidelines.11 The antiemetic regimens were categorized, con-
sistent with the antiemetic options in MASCC/ESMO 2010
Guidelines, as single-agent therapy (5HT3-RA), doublet therapy
(5HT3-RA and corticosteroids), and triplet therapy (NK1-RA,
5HT3-RA, and corticosteroids).
Although some other variables might be implicated in the
occurrence of CINV according to previous reports, such as
anxiety, fatigue, and anticipation of CINV development;14 they
were excluded from our study because these subjective variables
are poorly accessible in clinical practice. Besides, the impact
of these subjective variables on CINV development was very
limited compared with other demographic and clinical
variables.13 Their roles in the nomogram would probably be
compromising the feasibility rather than increasing prediction
accuracy.
Statistical Analysis
Complete response was adopted as an indicator of success-
ful prevention of CINV, which was defined as no vomiting and
no rescue therapy during the overall 120 hours postchemother-
apy. Although mild nausea might present in patients with
complete response, it remains an important goal for antiemetic
prophylaxis to protect patients from negative impacts due to
CINV.11 To identity predictors of CINV occurrence, multivari-
ate logistic regression analysis was used to test the association
between complete response and variables of interest listed
above.
The methods used to develop the nomogram were accord-
ing to those previously described.20,23 For the training cohort,
we used the bootstrapping method to validate internally. The
generalization of the nomogram was confirmed by external
validation using the validation set. The predictive accuracy
(discrimination) of the nomogram was measured via a con-
cordance index (c-index). Calibration plot was drawn to com-
pare how well the predicted probabilities from the nomogram
matched the actual probabilities. Bootstraps resample methods
with 100 repetitions were used for these activities.
All analyses were carried out using SPSS version 20 (IBM
Corp, Armonk, NY) and R 2.14.1 software with Package Hmisc
version 3.4-2. In all statistical analyses, a P value of<0.05 was
considered significant.
RESULTS
In total, 881 patients were collected in the present study,
with 565 for nomogram development and 316 for validation.
After excluding patients with missing data on BSA (n¼ 7),
alcohol consumption (n¼ 7), CINV evaluation (n¼ 2), and
history of motion sickness (n¼ 1), 548 subjects were enrolled
to the training set (N¼ 548), including 397 patients in P169
study (HEC), and 151 in the PrACTICE study (77 HEC and 74
MEC); their demographic and other baseline characteristics are
listed in Table 1. Excluding 2 patients without information of
alcohol consumption, a total of 141 cases with HEC and 173
cases with MEC in the PrACTICE study were included in the
validation set (N¼ 314), including 56 in Singapore, 142 in
South Korea, and 116 in Taiwan.
CINV event was presented in 37.2% of patients (204/548)
in the training set, with 40.0% in HEC population (180/474) and
Medicine  Volume 95, Number 2, January 201632.4% in MEC population (24/74); while in the validation set, it
was 28.4% (40/141) and 23.1% (40/173), in HEC and MEC
populations, respectively.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Demographic and Clinical Variables of the Training
Set and External Validation Set
Training Set
(N¼ 548)
External Validation
Set (N¼ 314)
Variables n % n %
Sex
Male 334 60.9 138 43.9
Female 214 39.1 176 56.1
Age, yr
Median (range) 55 (20–77) 57 (22–85)
PS score
0 318 58.0 173 55.1
1–2 230 42.0 141 44.9
BSA
Median (range) 1.67 (1.18–2.18) 1.71 (1.31–2.19)
Primary cancer diagnosis
Lung 327 59.7 70 22.3
Breast 50 9.1 84 26.8
HNSCC 34 6.2 8 2.5
Colon 32 5.8 61 19.4
Gynecologic 24 4.4 18 5.7
Stomach 20 3.6 15 4.8
Others 62 11.3 58 18.5
Alcohol consumption
<1 per week 461 84.1 275 87.6
>¼ 1 per week 87 15.9 39 12.4
History of motion sickness
Yes 23 4.2 53 16.9
No 525 95.8 261 83.1
History of VP in female
Yes 48 22.4 81 51.6
No 166 77.6 76 48.4
Emetogenicity of chemotherapy
HEC 474 86.5 141 44.9
MEC 74 13.5 173 55.1
Antiemetic therapy
Single-agent 40 7.3 25 8.0
Doublet 309 56.4 206 65.6
Triplet 199 36.3 83 26.4
BSA¼ body surface area, Doublet¼ 5HT3-RAþcorticosteroid,
HEC¼ highly emetogenic chemotherapy, HNSCC¼ head and neck
squamous cell carcinoma, MEC¼moderately emetogenic chemother-
apy, PS¼ performance status; Single-agent¼ 5-HT3 receptor antagon-
TABLE 2. Selected Variables According to Multivariate Logistic
Regression Model
Variables Odds Ratio 95% CI P Value
Sex and VP
Male Ref
Female without VP 1.87 1.18–2.97 <0.01
Female with VP 3.96 1.93–8.10 <0.01
Age, yr 0.99 0.97–1.01 0.34
BSA, m2 0.32 0.09–1.14 0.08
Alcohol consumption
No Ref
Yes 0.61 0.34–1.11 0.11
Motion sickness
No Ref
Yes 0.91 0.36–2.33 0.85
Emetogenic level
MEC Ref
HEC 1.86 1.02–3.40 0.04
Antiemetic therapy
Single-agent Ref
Doublet 0.89 0.43–1.86 0.76
Triplet 0.49 0.22–1.08 0.08
BSA¼ body surface area, CI¼ confidence interval, Doublet¼ 5HT3-
RA plus corticosteroid, MEC/HEC¼moderately/highly emetogenic
chemotherapy, Ref¼ reference, Single-agent¼ 5HT3 receptor antagon-
Medicine  Volume 95, Number 2, January 2016 Nomogram Predicting CINV After HEC/MEC TreatmentEstablishment of CINV Nomogram
First, we assessed the predictive value of each variable
through logistic regression. Table 2 lists the selected variables
with odds ratio and P values: sex (with females stratified by
history of VP) (P< 0.001), age (P¼ 0.339), alcohol consump-
tion (P¼ 0.108), history of motion sickness (P¼ 0.847), BSA
(P¼ 0.079), emetogenicity of chemotherapy (P¼ 0.045), and
antiemetic regimens (P¼ 0.012). We finalized a nomogram that
integrated all the predictors (Figure 1), in which the most
significant predictors were: sex by VP, emetogenicity of che-
ist (5HT3-RA), Triple¼ 5-HT3RAþcorticosteroidþ neurokinin-1
receptor antagonist (NK-1RA), VP¼ vomiting pregnancy.motherapy, and antiemetic regimens. The C-index for CINV
prediction was 0.67 (95% CI, 0.62–0.72) in this nomogram. The
calibration plot for the probability of CINV showed an optimal
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.agreement between the prediction by nomogram and actual
observation (Figure 2A).
As several prediction variables were not statistically sig-
nificant in the training set, we performed another developing of
nomogram including only those significantly associated with
CINV (sex by VP, emetogenicity of chemotherapy, and antie-
metic regimens). The C-index for CINV prediction was 0.58
(95% CI, 0.53–0.63), which was less than the nomogram
including all predictors (P¼ 0.02).
External Validation of the CINV Nomogram
As previously reported, clinical data from other countries
were the most stringent test population for model validation.24
Using the subjects from Singapore, South Korean, and Taiwan
in the PrACTICE study, external validation was performed
subsequently. Figure 2B shows the calibration plot of the
nomogram.
The X-axis is the predicted CINV occurrence probability
estimated by the nomogram, and the Y-axis is the actual rates of
patients with CINV development. The solid line represents the
ideal reference line where predicted CINV corresponds to the
actual outcome, and the dash lines represent a 10% margin of
error. The actual CINV corresponded closely to the predicted
development and was always within the 10% margin of error.
The calibration plot for the probability of CINV showed a good
agreement between the prediction by nomogram and actual
observation (Figure 2B). The C-index for CINV prediction was
0.65 (95% CI, 0.58–0.72). Furthermore, we compared the
ist (5HT3-RA), Triplet¼ 5HT3-RA, corticosteroid, and neurokin-1
receptor antagonist (NK1-RA), VP¼ vomiting pregnancy.discrimination of the present nomogram with that of the
MASCC/ESMO 2010 Guidelines classification (HEC/MEC).
The discrimination of our nomogram was superior to that of
www.md-journal.com | 3
rece
mo
Hu et al Medicine  Volume 95, Number 2, January 201the current chemotherapy emetogenicity classification
(C-index¼ 0.54; 95% CI, 0.46–0.61).
DISCUSSION
We have developed and externally validated a practical
nomogram that is able to predict the individual risk of CINV
occurrence in cancer patients receiving HEC/MEC treatment.
This tool is easy to use thanks to the friendly interface and visual
graphics, instead of complex mathematical calculation. Person-
alized estimation of patient’s risk of CINV development could
help healthcare professionals prevent this common adverse event,
such as prescribing appropriate antiemetic agents or selecting
chemotherapeutic regimens. On the other hand, identification of
patients with low risk might avoid overtreatment in the CINV
prophylaxis according to the current antiemetic guidelines.
FIGURE 1. Prediction nomogram of CINV in cancer patients
chemotherapy-induced nausea and vomiting; HEC/MEC¼highly/CINV is a persistent issue in the management of cancer
patients receiving chemotherapy, especially the HEC and
MEC.5,25 The problem has been highlighted by the complicated
validation of prediction models.24
Previous studies have revealed that earlier CINV onse
would increase the probability of CINV in subsequent cycles o
FIGURE 2. Calibration plots for the probability of CINV in nomogram and actual observation in the training set (A) and in externa
validation set (B). The X-axis represents the predicted CINV probabilities estimated by the nomogram, and the Y-axis is the actual rates o
CINV development. The solid straight line means the ideal reference line where predicted CINV corresponds to the actual outcome, an
the dashed straight lines represent a 10% margin of error.
4 | www.md-journal.com Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved6mechanisms of CINV development,26 the following refractory
situation after its initial onset,10 as well as the underestimation
from clinicians.7,27 Therefore, an approach that individually
predicts patient’s risk is critical to guide the precision medicine
in the management of CINV. In the present study, we enrolled
patients from 2 high-quality clinical studies on CINV preven-
tion in multiple countries. Using a practical tool of nomogram,
we built a prediction model for personalized estimate of CINV
development, which demonstrated an accuracy of 0.67 in over-
all patients revealed by the C-index. Importantly, this nomo-
gram was validated by independent data from an observational
study of CINV prevention, which reflected the real world of
clinician’s daily practice and patients CINV burden. Further-
more, the wide distribution of investigational sites (14 sites in
3 countries) in the validation set ensured this nomogram a large
extent of applicability, which was deemed the most stringent
iving HEC/MEC treatment. BSA¼body surface area; CINV¼
derately emetogenic chemotherapy; VP¼ vomiting pregnancy.t
f
l
f
d
.
chemotherapy,9,18,28 suggesting that the best ‘‘treatment’’ of
CINV is optimal prophylaxis prior to the first dosing of che-
motherapy. In our study, the development and prediction of
CINV was based on patient’s first cycle of HEC or MEC
treatment, which was supported by the importance of initial
CINV prevention. Although the antiemetic guideline consist-
ency is important for CINV prevention,6,8 however, once eval-
uated his or her CINV risk by this nomogram, a patient could
receive modified antiemetic regimens beyond the stereotyped
medications according to current guidelines. Besides the 5HT3-
RA, NK1-RA, and corticosteroid, some more antiemetic agents
have been demonstrated effective in the CINV prevention, such
as dopamine antagonists, ginger, histamine blockers, proton
pump inhibitors, and so on.29–31 Of these, olanzapine has been
studied in a wide range of population, which showed additional
CINV prevention when combined with standard triplet antie-
metic therapy.29 For those with high risk of CINV, clinicians
should consider a modified antiemetic regimen with additional
use of these unconventional antiemetic agents. Besides, some
other actions could be taken to prevent CINV, such as psycho-
logical intervention, lifestyle adjustment, or symptoms control
on fatigue or anxiety, as described in NCCN guidelines.12,32 The
nomogram is also helpful for those who have low risk of CINV
but presented contradiction toward recommended agents, such
as corticosteroid.33
As to predictors in the nomogram, we did not include all
the variables potentially associated with CINV in the present
study. Some subjective variables may impair the feasibility of
prediction model in clinical practice due to poor repeatability as
well as limited impacts on CINV, such as anxiety and fatigue.14
Besides, several variables in the final nomogram were not
statistically significantly associated with CINV in our training
set; however, these risk factors have been substantially studied
and confirmed previously. The inclusion of these predictors was
suggested by a superior prediction accuracy revealed by the C-
index (0.67 vs. 0.62). The lack of correlations might result from
limited sample size and positive cases with VP and motion
sickness history in the training set. Interestingly, the BSA
played an important role in the development of CINV in our
study, although the mechanisms underlying were not well
defined.
Despite many advantages of this prediction nomogram,
further work remains needed to make it more applicative in
future clinical practice. First, this nomogram only predicts the
CINV due to the first cycle of HEC/MEC treatment. Dynamic
prediction is necessary for effective CINV management, as the
probability of its occurrence would increase with the continu-
ation of chemotherapy.34 Second, predictors and their contri-
bution to CINV may be different in acute phase (<24 hours) and
delayed phase (24–120 hours) after chemotherapy. The mech-
anisms of CINV development during these phases are distinct
according to recent research;26,35 so it is necessary to figure out
such differences in CINV prediction in future studies, which
may increase the accuracy of CINV prediction. Furthermore, all
the patients in our study were from Asian countries, so its
applicability should be further investigated in other ethnic
populations. Nevertheless, this well-validated nomogram was
quite convincing and could help the personalized management
of CINV in clinical practice.
To conclude, the development and validation of a predic-
tion approach is critical in the personalized management of
Medicine  Volume 95, Number 2, January 2016CINV. The nomogram we presented here is an ease-to-use tool,
which could help healthcare professionals to estimate individual
risk of CINV development and then make proper clinical
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.decisions for cancer patients receiving HEC/MEC treatment.
Further studies are warranted to improve our understanding of
CINV development as well as personalized prophylaxis
of CINV.
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